Effective antibody therapies

Our products are the result of the extensive experience, expertise, and commitment of many employees and partners throughout the world.

Get to know us
Targeted cancer and rejection treatments

With our effective antibody therapies, we specifically influence the body’s immune system to fight malignant cells and to improve transplant tolerance.

Learn about our therapeutic areas
Innovation and optimization of existing products

Solving unmet medical needs through continued development of new and existing antibody technologies.

Products and pipeline
Creating the future together

Find out more about our focus areas and offers for our partners. We look forward to shaping the future with you.

Become a partner
Neovii Biotech: Effective antibody therapies

Welcome to Neovii Biotech

Whether you are a physician, journalist, patient, investor, future employee, or partner, this website is intended to present the aspects of our biotechnology company that interest you most.

Travel through time to experience our company history or get an overview of Neovii Biotech under Facts and figures.

Find out more about Therapeutic areas in which we are active or get information about the Neovii Biotech Products and developments.

If you cannot find the information you are looking for, do not hesitate to Contact us. We are looking forward to getting to know you and answering your questions about Neovii Biotech.

Our products

We focus on effective antibody therapies. Find out more about our products ATG-Fresenius® S and Removab®.

To the Neovii Biotech products

Press

28|06|2013

Fresenius sells biotechnology business

Continue reading

02|10|2012

ESMO 2012: New phase IIIb study confirms the shorter infusion time, efficacy and safety of catumaxomab in malignant ascites

Robust data confirm the clinical relevance

Continue reading

04|10|2011

Fresenius Biotech obtains reimbursement approval for Removab® antibody in Belgium

Continue reading

20|09|2011

Removab® receives approval for a shorter infusion time in treating malignant ascites – one-year survival rate in Removab®-treated patients is more than four times higher

Continue reading

22|06|2011

Fresenius Biotech obtains reimbursement approval for Removab® antibody in Italy

Continue reading

07|06|2011

ASCO 2011: Fresenius Biotech presents new data for the trifunctional antibody Removab® − benefit in overall survival of cancer patients demonstrated

Continue reading

06|06|2011

Fresenius Biotech’s ATG-Fresenius® S approved in Austria for GVHD prophylaxis in stem cell transplantations

Continue reading

07|03|2011

Fresenius Biotech’s ATG-Fresenius® S approved for GVHD prophylaxis in stem cell transplantations in Germany

Continue reading

27|01|2011

Fresenius Biotech announces agreement with Swedish Orphan Biovitrum for distribution of Removab®

Continue reading

21|10|2010

Removab® (Catumaxomab) wins Galenus-von-Pergamon award

Continue reading

07|06|2010

Fresenius Biotech presents new data on trifunctional antibody Removab® at 46th ASCO Annual Meeting in Chicago

Continue reading

07|01|2010

Fresenius Biotech launches new corporate website

Continue reading

23|04|2009

Removab® receives marketing approval

European Commission grants marketing authorization for Removab®

Continue reading

18|02|2009

EMEA Committee recommends marketing approval

The European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) today issued a positive opinion recommending approval of Removab for the intraperitoneal treatment of malignant ascites.

Continue reading